Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
May 6, 2020
Earnings Call Speaker Segments
Diane Weiser
executiveHello, and welcome, everyone, to today's call. Robert Blum, who serves as our President and Chief Executive Officer, is going to get things started by walking through the quarter and discussing how COVID-19 has affected some of our clinical trials. Then Fady Malik, our EVP of Research and Development, will share the latest on omecamtiv mecarbil, the cardiac myosin activator we're developing, and AMG 594, our cardiac troponin activator — both of these sit within our collaboration with Amgen. After that, Stuart Kupfer, our SVP and Chief Medical Officer, will speak to recent advances with CK-274, a wholly owned cardiac myosin inhibitor that has reached phase II, and CK-271, our other cardiac myosin inhibitor. Robert Wong, our VP and Chief Accounting Officer, will then give a financial overview covering the quarter, and Ching Jaw, our SVP and Chief Financial Officer, will talk through corporate development strategies, after which Robert Blum will offer closing remarks about the company's outlook, which will include news on reldesemtiv, our fast skeletal muscle troponin activator, plus the key milestones we expect for the rest of the year. I'd like to point out that parts of what we discuss next, including answers we give to your questions, will contain statements about future events and performance instead of historical facts, and these qualify as forward-looking statements. Among examples of such statements are ones concerning the potential effects of the COVID-19 pandemic on our research and development activities and business operations, which includes our anticipated cash expenditures during the 2020 calendar year. There are also statements about Cytokinetics and its partners' research and development and commercial readiness activities, which take in the initiation, conduct, design, enrollment, progress, continuation, completion, timing, and results of clinical trials. What actually happens to us could differ materially from what these forward-looking statements project. You can find additional information about factors that could make our actual results differ materially from those in these forward-looking statements in our SEC filings. We have no obligation to update any forward-looking statements after this call ends. With that, I'll hand the call over to Robert.
Robert Blum
executiveDiane, thank you, and once more, I appreciate all of you taking part in today's call. To kick things off, I'd like to send you and your loved ones our hopes for safety, health, and well-being amid these unprecedented and uncertain times. Nothing matters more to us than the health, safety, and well-being of our employees, clinical trial participants, and business and community partners. Under California and Bay Area shelter in place orders, our employees have been working mainly from home and will keep doing so. Because of that, no business travel is taking place, and like many of you, we've been attending medical and investor conferences virtually. Throughout this period, we're making every effort to keep the vital work needed to bring our potential medicines to patients moving forward. With that in mind, on today's call we'll bring you up to date on progress made during the quarter and, in particular, how the COVID-19 pandemic has affected and has not affected our business and operations. Although we've chosen to temporarily halt enrollment in some of our clinical trials, we remain on schedule to report top-line results from GALACTIC-HF during Q4. Fady will say more about that key strategic objective shortly. We started 2020 at full speed with a busy and productive first quarter. As we've said before, our main focus this year is our cardiovascular pipeline, which today features four drug candidates moving ahead across every stage of development. The standout achievements of the quarter revolved around GALACTIC-HF, one of the biggest phase III global cardiovascular outcome studies in heart failure, run by Amgen through our long-standing collaboration; among those recent achievements were, first, publication of the trial's design manuscript. Then came our clearing the second and final planned interim analysis of GALACTIC-HF, with the DMC recommending no changes to how it is conducted. Last was the virtual presentation at ACC 2020 of baseline characteristics and demographics from GALACTIC-HF. Fady will go into these items specifically; it's enough to say we're pleased that the trial enrolled the high-risk patient population the design and protocol called for. As the design paper explains, this clinical trial will contain the largest number of cardiovascular events ever accumulated in a heart failure trial; during the first quarter of this year, we also opened REDWOOD-HCM, the phase II clinical trial of CK-274, our next-in-class cardiac myosin inhibitor for potentially treating obstructive hypertrophic cardiomyopathy. We announced not long ago that enrollment in REDWOOD-HCM is temporarily suspended. We're carrying on startup activities with the goal of activating additional sites in both North America and Europe. Stuart will describe how those startup activities are progressing and how we intend to ride out the COVID-19 storm. Last quarter, we shared important preclinical data on CK-274, which detailed its mechanism of action and its properties for modulating cardiac contractility in vitro and in vivo. The results showed a unique, targeted attachment point for CK-274, and our view is that this may open up possible uses in treating patients. In addition, we shared preclinical findings on AMG 594, the cardiac troponin activator we are developing alongside Amgen; this was the inaugural scientific disclosure of how AMG 594 works, and it featured evidence pointing to a beneficial pharmacodynamic window. While enrollment in the phase I trial of AMG 594 is paused for now, we are eager to see results from that study once they become available. Even with the changed circumstances brought about by the coronavirus, our team remains more dedicated and driven than ever to push forward our goal of delivering medicines with novel mechanisms to people battling muscle dysfunction diseases. I remain deeply inspired by the enthusiasm and dedication of our staff, and I want to reassure you that we are making every effort to keep the essential work going that is needed to get our prospective treatments to patients. Having said that, I will now hand the call to Fady, who will discuss in more detail the important progress made under our Amgen partnership.
Fady Malik
executiveAppreciate that, Robert. Like Robert just walked through, our work with Amgen led to a number of important achievements in Q1 — we got the design manuscript for GALACTIC-HF published in JACC: Heart Failure, we cleared the second and final planned interim analysis performed by the data monitoring committee, and just recently we shared the baseline characteristics and demographics of the patients who were enrolled. I went over those first two milestones on our Q4 earnings call, so today I'll zero in on a few key takeaways from the GALACTIC-HF baseline characteristics, plus how Amgen is moving forward to keep the trial running smoothly and to report top-line results in Q4 2020. Our design for GALACTIC-HF means the enrolled population is a heart failure cohort that continues to run a risk of cardiovascular events even when they get solid treatment with standard therapies. Baseline characteristics from this trial show a nicely balanced mixture that spans countries worldwide and includes care delivered both in hospitals and in clinics. As you may remember, each outpatient in GALACTIC-HF had to have a hospitalization within the prior year, and even so, the median time since the most recent heart failure hospitalization or heart failure ER visit in GALACTIC-HF comes to three months, which fits with enrolling a group whose likelihood of being rehospitalized or dying from cardiovascular causes is raised. Also, just to remind everyone, during the index heart failure hospitalization, 25% of the patients were randomized. So this is a patient group that's a bit sicker and more symptomatic, and you can see that in their higher median NT-proBNP, along with lower blood pressures, lower estimated glomerular filtration rate, and lower baseline Kansas City Cardiomyopathy Questionnaire scores. The data also show that in GALACTIC-HF, adherence to standard of care background medical therapy is quite good — 94% of patients on beta blockers, 87% on renin-angiotensin system blockers, and 77% on a mineralocorticoid antagonist. And on top of that, many of you have been interested in the percent of patients in GALACTIC-HF being treated with ENTRESTO. Just about 20%—more than 1,500 individuals—receive a treatment regimen that features ENTRESTO. We ought to get a solid read on whether omecamtiv mecarbil can lead to better results for those on ENTRESTO. To understand where the GALACTIC-HF patient group stands, it helps to set their cardiovascular risk profile against those of other heart failure outcome trials that have reported recently. Regarding markers of future cardiovascular event risk—NT-proBNP is one important instance—the baseline profile for people enrolled in GALACTIC-HF appears to land in the middle. On one end, you have the lower-risk populations from PARADIGM-HF and DAPA-HF, as well as the phase III studies for ENTRESTO and FARXIGA. On the other side is the higher-risk group from VICTORIA, the phase III study of vericiguat presented not long ago at ACC 20. Amgen and we built GALACTIC-HF's design around enrolling people at greater risk than those in PARADIGM-HF, and one specific requirement was that 25% of participants be randomized from the hospital setting. Even so, the population remains broadly representative of most heart failure patients who continue to face cardiovascular event risk. The GALACTIC-HF patient group spans multiple geographies and remains very effectively treated with standard care. Our belief is that this study could deliver clinically meaningful proof of how cardiac myosin activation, a novel mechanism, might prove important for potentially treating chronic heart failure. Now regarding COVID-19 and how GALACTIC continues to run right now; both we and Amgen remain committed to the previously stated plan of locking the database and moving forward to report top-line results during Q4 of 2020. Events keep accumulating, and we are watching them carefully. Let me remind everyone that in February, when the DMC carried out its second and final scheduled interim analysis, that review had been prompted by reaching two-thirds of the 1,590 CV deaths targeted; for that review to take place at that moment, the triggering event needed to have happened during the fourth quarter of 2019, with further events accruing right up until the interim analysis occurred. That review gave us a chance to gather, clean, and examine a substantial majority of the clinical trial data. As a result, it ought to make final trial database lock easier later this year. During this whole COVID-19 situation, many patients no longer enjoy the same ability to reach their study centers as before; despite that, the way the trial operates has been changed by Amgen so that the investigational product may be shipped to where patients live, and endpoint-collection study visits may take place remotely. Right now, for the primary endpoints — heart failure events, CV death, and the Kansas City Cardiomyopathy Questionnaire given at week 24 — there's no requirement that patients come to trial sites in person. At Amgen, a tremendous amount of logistics and planning work is going on to prepare for trial closeout. My thanks go out to our colleagues at Amgen, the investigators and their staff who are running our clinical trials, and the patients as well, for everything they're doing to adapt in these extraordinarily difficult circumstances. All things considered, because of how far along we are with conducting the GALACTIC-HF trial, I think we're in a fortunate position. You might have noticed that clinicaltrials.gov was recently updated with a study completion date of August 7th, so we're still on schedule to share top-line results in Q4. Now, regarding the second phase III trial for this program, METEORIC-HF, the coronavirus pandemic has led us to temporarily halt enrollment. We're continuing to prioritize startup activities so that more active sites can be added once enrollment resumes; specifically, we aim to bring a substantial number on board in Europe. As conditions in Europe improve, quite a few sites are already prepared to take part in METEORIC-HF, and we continue striving to reach the objective of bringing on more than 50 new sites throughout North America and Europe. When clinical research can begin again at clinical sites, we could very well be in a position to advance screening and enrollment over the coming months. Even though we stopped screening new patients, we're making sure that those who'd already started investigational treatment but hadn't finished the trial before we halted enrollment of new patients are still being monitored remotely. Should enrollment restart by the close of Q2 2020, our belief is that we could still finish enrolling before the year ends. To reiterate what we've mentioned previously: the results coming out of METEORIC-HF are not essential for us to move forward with regulatory submissions seeking approval for omecamtiv mecarbil. Instead, if what METEORIC shows turns out to be favorable, that data would be included in a supplemental submission filed after a potential commercial rollout, which itself would be based on what we learned from GALACTIC-HF. Turning now to AMG 594—Robert noted that preclinical data on this compound were shared during the quarter at the Keystone Symposia focused on heart failure. We were glad to present bench research showing that AMG 594 raises calcium sensitivity specifically in cardiac muscle fibers and boosts the heart's ability to contract. This backs up the idea of going after cardiac troponin activation as a potential strategy for treating conditions marked by reduced systolic function. Findings from animal studies also suggest that AMG 594 may have a favorable pharmacodynamic window. As we said before, because of the COVID-19 pandemic, we have temporarily halted enrollment in the single ascending dose and multiple ascending dose phase I study of AMG 594. Even so, we look forward to seeing data from this trial, as it may inform a potential next step into phase II. Speaking of which, we're working alongside Amgen to finalize the design for our phase II study; with that, I'll pass it over to Stuart, who can bring you up to speed on where things stand with our cardiac myosin inhibitor program.
Stuart Kupfer
executiveThanks for that, Fady. As you likely know, our program focused on cardiac myosin inhibition includes both CK-274 and CK-271. To start, I'll update you on how site activation, screening, and enrollment are progressing in REDWOOD-HCM, the phase II trial evaluating CK-274 as a possible treatment for obstructive HCM. Then I'll discuss where things stand in terms of our readiness for the phase I study of CK-271. In response to the coronavirus pandemic, Cytokinetics formed an internal task force focused on clinical trials and implemented a business continuity plan for studies already underway. We are in touch with our CROs and other vendors regarding their own business continuity plans, and we have been tracking clinical trial site policies related to ongoing research and hospital access. Similar to what we did for METEORIC-HF, enrollment in REDWOOD-HCM has been paused for the time being as a way to safeguard the well-being of people taking part in the study and the medical staff caring for them. That said, we have kept working with the trial sites to make sure those already enrolled can still receive investigational product, and to allow for remote visits whenever that's possible. At the same time, our internal teams are continuing to coordinate with our CROs, vendors, and sites on bringing new sites online, with a goal of getting more than 20 additional sites up and running throughout North America and Europe. I want to point out that in this trial we'll be turning on a greater number of sites than the patients we actually require for each cohort. Our hope is still that if we can finish enrolling the first cohort by the middle of the year, then data from cohort 1 could be in hand by the end of the year. Robert already noted that preclinical findings on CK-274 were shared at the Biophysical Society Annual Meeting held recently. What those findings demonstrated is that in vitro, CK-274 lowers cardiac myosin activity, and just as importantly, it leaves smooth muscle myosin activity uninhibited — evidence that it selectively targets cardiac myosin. The study also showed that CK-274 binds at an allosteric site that is not the same as mavacamten's, and that could set apart the pharmacodynamic profiles of these two drug candidates, both of which look promising. Regarding CK-271, which is another of our cardiac myosin inhibitors, we're happy to share that during Q1 the IND was submitted and accepted, and study startup work has started for a phase I trial of CK-271 involving healthy volunteers. This initial human phase I trial's main goal is evaluating safety, tolerability, and pharmacokinetics for single ascending oral doses of CK-271 among healthy adult subjects. Our expectation is still that we can kick off this trial in Q2. That said, just like with the rest of our studies, when we begin will be shaped by how circumstances develop at the location where we run it. With that, I'll hand things over to Robert Wong for an update on our financials.
Robert Wong
executiveThank you, Stuart. To start, I'll give you an update regarding our cash position, revenue, and expenditures. Ching is going to walk through the 2020 financial guidance we've set, along with our approach to corporate development. You can find additional information about what we actually delivered in the first quarter of 2020 in the press release that went out earlier this afternoon. We closed out the first quarter holding roughly $237 million in cash and investments. During Q1 2020, our revenue was generated through strategic alliances with Amgen and Astellas. When it comes to Amgen, we recorded revenue tied to their reimbursement of our development costs for METEORIC-HF. As for Astellas, we booked revenue from reimbursement of expenses connected to our scientists who took part in collaborative research. R&D expenses for the first quarter of 2020 declined to $21.7 million, compared with $23.5 million during the same period in 2019. That drop was mainly the result of reduced spending on our neuromuscular development work, following the completion of FORTITUDE-ALS in 2019, which was partly offset by greater activity on both METEORIC-HF and REDWOOD-HCM during 2020. As anticipated, over 50% of our R&D expenses went toward our cardiovascular program, reflecting work on METEORIC-HF and the cardiac myosin inhibitor program, while the rest of our expenses were mainly tied to early-stage research efforts. G&A expenses for Q1 2020 reached $12.4 million, an increase from $9.4 million in Q1 2019, driven largely by greater personnel-related costs, such as stock-based compensation, as well as more spending on outside services. At this point, Ching will go over our 2020 guidance and discuss the highlights of our corporate development strategy.
Ching Jaw
executiveAppreciate it, Robert. For 2020, our projection remains that cash revenue will land somewhere between $18 million and $22 million. We expect operating expenses to fall in the $120 million to $130 million range, while net cash utilization across the entire year should come in somewhere between $105 million and $115 million. In light of the coronavirus and the possible effects on our clinical studies and operations, we're keeping a close eye on our spending, and should it appear that our spending could shift, we may revise financial guidance at a later point in the year. Throughout the quarter, we kept looking for chances involving project financing, royalty monetization, and partnerships, with the goal of broadening development of our cardiac sarcomere inhibitor program and further lengthening our cash runway. Momentum for these conversations comes from progress on REDWOOD-HCM as well as the phase I study of CK-271; on top of that, assuming favorable results from GALACTIC-HF, we stand to receive roughly $100 million in milestone payments through our collaboration with Amgen across the coming 12 to 18 months; we feel lucky to have a solid financial position, particularly considering the uncertainty in today's equity capital markets, and we keep working to make certain we deploy capital wisely toward our prioritized clinical programs so that shareholder returns are maximized. Having said that, I'll hand the call back to Robert Blum.
Robert Blum
executiveI appreciate that, Ching. We are living through genuinely remarkable days. In earlier periods, Cytokinetics has made it through difficulties in business. Just as we've managed previously, the people who work here are meeting this moment, looking ahead and placing priority on their wellbeing and on what we're trying to accomplish. I feel tremendous pride in the spirit of fellowship and the way we've worked together, both among ourselves and alongside our partners in business. Even with these more recent hurdles, nothing has shifted in our resolve toward groundbreaking science and toward patients, and our commitment has held steady. Our outlook stays hopeful that this could turn out to be a year of transformation for the organization, and it's good to know that our most valuable program, omecamtiv mecarbil, is still on schedule to deliver top-line registration trial results during Q4 of this year. I'd also like to give an update on reldesemtiv and on how we're working with Astellas. Not long ago, we filed an 8-K concerning our signing of agreements that, considered together, modify and replace the collaboration agreement covering research, development, and commercialization that we hold with Astellas. Following up on the agreement in principle we had already made public, through these amendments Cytokinetics gains exclusive control over and responsibility for developing and commercializing reldesemtiv, CK-601, and additional fast skeletal regulatory activator compounds. Astellas committed to covering specific costs, as much as $12 million, potentially arising from a possible phase III clinical trial by Cytokinetics of reldesemtiv in ALS, a trial we estimate might run roughly $30 million to $40 million, spread across multiple years. Beyond that, Astellas consented to non-cash contributions to Cytokinetics, among them handing over its inventories of active pharmaceutical ingredient for reldesemtiv and CK-601, plus carrying on ongoing stability studies at its own expense. In exchange, Cytokinetics would owe Astellas a royalty in the low-to-mid single digits on reldesemtiv sales in particular countries, should commercialization occur. On top of that, Astellas has prolonged the joint research program at Cytokinetics for the rest of this year, with Astellas supporting no fewer than 15 research FTEs, and it holds exclusive rights to co-develop and co-commercialize skeletal sarcomere activators apart from fast skeletal regulatory activator compounds across all indications, subject to specific Cytokinetics development and co-commercialization rights. Cytokinetics is permitted to co-promote and carry out certain commercial activities across the U.S., Canada, and/or Europe. We're glad to have these new agreements completed and anticipate our partnership with Astellas continuing, aimed at skeletal muscle activation. Also, when it comes to reldesemtiv, we held a Type C meeting with FDA during Q1, where FDA gave helpful input on the phase III clinical trial design we proposed along with its endpoints and statistical plan, input that will shape how reldesemtiv is developed further. In the interim, we're arranging further interactions and meetings with EMA and with HTAs so as to help finalize the potential protocol. Like we said earlier, no final calls are going to be made about a possible phase III study of reldesemtiv in ALS patients until we can see what comes out of GALACTIC-HF along with the cost of capital tied to it, which we anticipate later this year. To wrap up, we're heading through 2020 from a solid spot operationally and financially, and we're eager to keep bringing you updates on our pipeline of novel mechanism drug candidates as it moves forward, plus our additional groundwork for possible commercialization efforts. Let me run through the milestones we anticipate for 2020. On omecamtiv mecarbil, top-line results out of GALACTIC-HF should arrive in the fourth quarter, and we think enrollment could wrap up in METEORIC-HF among heart failure patients during 2020, provided we're able to restart enrollment before Q2 2020 ends. On AMG 594, Amgen and Cytokinetics have mutually decided to halt enrollment in that phase I trial. On CK-274, data from the initial cohort of patients dosed in REDWOOD-HCM ought to be on hand during the back half of 2020, assuming the first cohort finishes enrolling by the middle of the year. On CK-271, a phase I study should kick off prior to the close of Q2 2020. On reldesemtiv, we'll keep working with regulatory and reimbursement authorities throughout 2020 so we're ready for a possible phase III clinical trial and registration program among ALS patients. As for research that's ongoing, we'll keep up activities aimed at the cardiac and skeletal sarcomere along with our other muscle biology research programs. Our research collaboration with Astellas, focused on finding next-generation skeletal sarcomere muscle activators, will also carry on through 2020. Operator, that being said, please go ahead and open the line for questions. Hello, Charles.
Pete Stavropoulos
analystHey there, Pete here, filling in for Charles. How's it going?
Robert Blum
executiveDoing really well, thanks. And yourself?
Pete Stavropoulos
analystGreat, and congratulations on everything you got done during this quarter. It's good to hear you confirm that GALACTIC remains on schedule to deliver top-line data before the year is out. My question is this: now that FARXIGA has recently won approval for heart failure with reduced ejection fraction, I'd like your take on the market opportunity and the unmet need. Also, when it comes to omecamtiv, which obviously works through a differentiated mechanism of action, how do you think the market will receive it?
Robert Blum
executiveThat's a really good question. I'll give my answer, and then I'll have Fady add some detail. As for that new drug cleared for treating heart failure with reduced ejection fraction only yesterday, as you're aware, it has been on the market for diabetes patients for several years, and more recently it has shown impressive activity in treating heart failure with reduced ejection fraction. Our view is that it will help drive greater education and awareness of the still very high unmet need when it comes to treating heart failure, and of how important new mechanisms are for bringing down the high morbidity and mortality. We think it will help illuminate what benefit may come from enhancing cardiac muscle function with omecamtiv mecarbil as it relates to potentially complementary therapies. With that, I'll hand things to Fady to elaborate.
Fady Malik
executiveYes, I believe dapagliflozin, which is marketed as FARXIGA, marks a step forward when it comes to heart failure. Even in that particular study, patients received good treatment under other standards of care, and the group was possibly less sick, yet you still saw CV death — that means mortality — event rates of 7%-8% each year; to put that in perspective, it's triple the event rate observed in big atherosclerosis trials and similar studies; when you look at something like VICTORIA, reported not long ago in a more severely ill group, we'd expect event rates for the primary outcome to land around 30%. As we keep developing and witness fresh approvals for heart failure therapies, the unmet clinical need here remains enormous; it places a huge financial strain on our society and ranks among the most frequent conditions affecting those who are middle-aged or older. Our view is that omecamtiv will, provided GALACTIC-HF delivers positive results, have the potential to join this foundation for heart failure. A key difficulty, in my view, as heart failure care keeps evolving, will be figuring out the order in which these drugs get used. What we appreciate is that omecamtiv, similar to dapagliflozin, carries a very favorable profile in that it has no impact on blood pressure, causes no harmful effects on kidney function, and so on. It's fairly simple to administer, and that, I think, explains the interest people have in dapagliflozin.
Pete Stavropoulos
analystOK, thanks. That was really helpful. Congrats once more on the quarter.
Robert Blum
executiveThanks.
Fady Malik
executiveI appreciate it.
Pete Stavropoulos
analystThanks.
Robert Blum
executiveHi there, Salim.
Dennis Ding
analystDennis here, filling in for Salim — hey everyone. Appreciate you fielding this, and nice work on what you've accomplished so far. Two things from me. To begin, regarding GALACTIC-HF, what's your view on what counts as a clinically meaningful gain on the primary endpoint, and on CV death too?
Robert Blum
executiveThat's a great question, thank you. Once more, I'll kick things off, then hand off to Fady and Stuart if he'd like to chime in further. On GALACTIC-HF, what I'd note is that with recent studies involving ENTRESTO, vericiguat, and DAPA now available, we can look at similarities and differences in CV death reductions, plus other endpoints. In certain ways it's truly comparing apples to oranges, since those trials ran at separate times, in separate populations, under separate risk criteria. That said, assuming a drop in event rate somewhere around 10%-20% strikes me as reasonable, and that magnitude matters meaningfully and carries clinical significance. The more that skews toward the upper portion of that band for CV death, the more visibility it gains — even substantially so — among clinicians. We won't attach any further specifics beyond that, except to note GALACTIC-HF was built specifically to gather a substantial number of events and a substantial number of CV deaths, with a long median treatment duration, in patients carrying risk because they'd recently been hospitalized for acute heart failure, yet whose BNPs still sit in a range implying they remain salvageable, so to speak. Given all that, it's fair to anticipate that the GALACTIC-HF criteria capture a broad cross-section of heart failure patients with reduced ejection fraction — and crucially, those adding meaningfully to both high clinical burden and high economic burden. With that, I'll pass it to Fady to see what he'd like to add.
Fady Malik
executiveMy view is that when it comes to mortality, the bar for what's seen as clinically meaningful doesn't vary much across indications. A reduction of 10% or more tends to be regarded as a favorable mortality effect. In a study such as GALACTIC-HF, with such a high number of events, a gap of that size would remain reasonably statistically significant. You'd have at least solid confidence regarding the reliability of that result. Taking the two together, I believe once more, they land at 15%-20% or above. If you consider the other heart failure treatments, sometimes the issue isn't what counts as clinically meaningful, but rather how you position yourself relative to the therapies that preceded yours. Stuart, I'm not sure whether you'd like to add anything there.
Stuart Kupfer
executiveAppreciate that, Fady. The one thing I'd tack on relates to what you said about GALACTIC-HF having brought in a population at very high risk. Sure, paying attention to the relative risk reduction matters, but you also can't overlook the absolute risk reduction. That really captures the overall burden of disease. Bringing down that absolute risk reduction is something worth weighing too.
Dennis Ding
analystGot it. That's very helpful.
Robert Blum
executiveThanks, Stuart.
Robert Blum
executiveHey there, Joe.
Joe Pantginis
analystHi, everyone. Good afternoon. I hope you and your families are all doing well. I think my question also ties into a good opportunity to remind us about the CK-274 program. With the upcoming results from the EXPLORER-HCM study for mavacamten, you're going to see a significant increase in visibility. So, two things. First, can you remind us — you do have potential financial benefit from the mavacamten program. I believe you get a royalty. Can you just remind us some of the details? Second, I don’t see the EXPLORER-HCM trial as something that would necessarily produce a clear-cut result, or as something that would determine how your own trial or program for CK-274 moves ahead. If EXPLORER-HCM doesn’t succeed, there could clearly be a short-term spillover effect on CK-274. I’d appreciate it if you could explain why that negative spillover might not have to happen, given the differing therapeutic profile. Thank you.
Robert Blum
executiveThanks, Joe. I’ll address that from a few angles, and then I’ll hand it to Fady. To start, we're hoping EXPLORER-HCM turns out positive; we believe there's a real chance it will be, and we think that would matter a great deal for patients, particularly as confirmation of this mechanism in what could become an approved use. That said, our work on CK-274 is moving ahead just as it has been. Our plan is to study the data that comes out of EXPLORER-HCM closely, so that we can push the field forward in a way that helps both mavacamten and CK-274, and in the end benefits patients. And you're correct that once mavacamten is commercialized, we do get a royalty on it. Just so we're clear, the royalty sits in the low single digits, yet given how we took part in getting that company off the ground and helped synthesize mavacamten, that rate still makes sense. That being said, our view is that CK-274, as any solid follow-on drug candidate would be, was built with distinguishing characteristics that could give it particular next-generation advantages and help push the clinical work forward and possibly the commercialization too. I'll now hand things to Fady, who can go into the specifics in more detail.
Joe Pantginis
analystYeah. Hey, Joe. Those data could end up being pretty complex, I'd say. We feel good about the way this mechanism of action could benefit these patients and help their function improve. And when we look at what comes out, I believe it will guide us regarding any adjustments we may weigh for our development program — for instance, whether we'd want to revisit the primary endpoint — and also help us grasp how the pharmacokinetic and pharmacodynamic characteristics of CK-274 might behave given what mavacamten is doing in these patients. That's a really useful experiment now underway. Are you all still with us? I believe Fady dropped off.
Robert Blum
executiveFady's audio cut out.
Joe Pantginis
analystAll right. Regardless, I found that quite useful. Thanks a lot.
Robert Blum
executiveOf course. Appreciate it, Joe.
Fady Malik
executiveCan you guys hear me? We can hear you now, buddy.
Jason Butler
analystHello, and thank you for fielding the question. I have one regarding Redwood. Could you provide some perspective on the progress you've made so far?
Chad Messer
analystWonderful, thank you. I'll go ahead and presume everyone can hear us properly. Joe raised a compelling point regarding the forthcoming mavacamten results. I'd actually like to revisit and hear your perspective on a separate mavacamten development, which was the MAVERICK findings in non-obstructive HCM. When we last discussed this, I recall we were eager to learn how those results would turn out, particularly in terms of shaping your views on a non-obstructive program for CK-274; those findings are now available. They first emerged last year, though they were shared in March at the virtual ACC. I'm curious what you make of that, and how it influences your assessment of the odds for conducting a non-obstructive HCM trial.
Diane Weiser
executiveWe're encountering an issue with Robert's audio.
Diane Weiser
executiveLooks like Robert's trying to dial back in.
Stuart Kupfer
executiveThis is Stuart. Can you hear me?
Diane Weiser
executiveYes, Stuart.
Stuart Kupfer
executiveCorrect. Yeah. Regarding what Chad asked about MAVERICK-HCM, obviously we know about the data from MAVERICK-HCM. It was definitely a solid proof of concept study backing the use of a cardiac sarcomere inhibitor in a non-obstructive HCM population. That does back our strategy of considering a cardiac sarcomere inhibitor for that population. It fits into an overall strategy we are planning. As for the matter of it, we are still thinking about the exact strategy and the timing for when we move forward to study that population. We found the results encouraging, and it is a good proof of concept.
Chad Messer
analystAlright, excellent. Thanks. There was just one additional item I wanted to raise. I'll go ahead and mention it. This is really a strategy-oriented inquiry; it might tie into certain Vision 2025 objectives you have. Naturally, we all know that the arrangement with Amgen included an option, which you have exercised, to co-promote, and through that you hold the ability to deploy a sales team working in hospitals. That sales force is fairly specialized, but I'm simply curious about how possessing something like that aligns with your longer-term strategic aims.
Diane Weiser
executiveI'm able to address that while Robert and Fady are attempting to rejoin.
Fady Malik
executiveFady, are you able to hear me, Diane?
Diane Weiser
executiveOh yes, Fady. Would you like to handle that one? I had intended to chime in, but please, go ahead.
Fady Malik
executiveI'll take a crack at it. Normally Robert handles these kinds of questions better than I do. What we're really doing strategically, I think, is building an institutional sales team capable of engaging with the big providers, the big thought leaders, the big medical centers, the top heart failure institutions. As we've mentioned previously, that team is enabled by Amgen. Amgen foots the bill. It provides us with an early advantage in building a field-based sales organization, which clearly, at that point, if 274 works out, would hand us an early advantage when it comes to commercializing it. We're quite happy with how the deal came together as part of our approach when it came to negotiating that initial agreement, along with other later agreements, to support Cytokinetics' growth as a company into that capability. It aligns nicely with our approach of building a cardiovascular footprint, truly, from research all the way through to commercialization.
Diane Weiser
executiveHello, everyone. Robert here. I believe I can be heard now. Fady has it exactly right, in my view. What I'd add is that this fits within a corporate development approach the company has followed for a long time, one in which we draw on our alliances to gain access to both capabilities and financial resources so that we can advance to a higher stage in our evolution as a business. When we consider the possibility of co-commercializing omecamtiv mecarbil, that effort sits inside a franchise plan aimed at institutional care and specialty cardiology segments, where our sales force, together with Amgen's, would co-promote omecamtiv across North America, under an arrangement in which Amgen reimburses some of our costs. That ought to allow us to reach positive marketing contribution much earlier than is usual after a company's first commercial launch.
Robert Blum
executiveThis will also put us in a position to operate within those centers where we anticipate CK-274, along with other products from our cardiovascular lineup, will likewise be brought to market. It's an R&D approach that goes side by side with our business development and corporate development strategy.
Chad Messer
analystAll right, thanks Robert and everyone on the team. I hope each of you keeps staying well and secure, and that no further tech problems come your way.
Robert Blum
executiveThanks, Chad.
Robert Blum
executiveHi there, Ted.
Edward Tenthoff
analystHi, everyone. How's it going?
Robert Blum
executiveDoing well.
Fady Malik
executiveEverything's fine. Thanks.
Edward Tenthoff
analystGreat, that's good to hear. I appreciate you answering my question. There's a lot of encouraging news. I'm genuinely looking forward to the GALACTIC data. The background you gave on that was especially helpful. What I'd like to ask about is partly reldesemtiv and the new Astellas partnership. From your perspective, I'd like to understand what would need to happen — whether through further data cuts or through talks — in terms of what you hope to accomplish with the FDA before you could truly conclude that this would be an investment worth making. Now that 601 has come back to you, is that a more potent compound, perhaps even a stronger candidate to advance? Many thanks.
Robert Blum
executiveThose are excellent questions. I'll begin and then hand things back to Fady. On your first point, regarding additional data cuts, we've already seen data — through pre-specified analyses and, admittedly, some post-hoc ones — that we view as compelling regarding what reldesemtiv might do in treating ALS. That being said, we still must make sure we can run a proper clinical trial — one that is both statistically and clinically relevant once finished, and that also produces results that could be meaningfully valuable to payers and reimbursement authorities; those discussions are ongoing right now. We're approaching this in a way that is, admittedly, painstakingly thoughtful. It's taking time, but we believe that time is well spent so that we have dotted all the I's and crossed all the relevant T's; the feedback we've already gotten from FDA and EMA encourages us, and so does what we're hearing as we engage reimbursement authorities and payers, but we're not done yet, and we are purposefully making sure those timelines line up with our ability to start a clinical trial in the fourth quarter if the GALACTIC-HF results are enabling of us and our cost of capital is such that we think this is the right thing to do by our science and by our shareholders. All of that is meant to indicate that we are very optimistic, and we are very encouraged already by the interactions that we've been having. Fady, anything you want to elaborate on that?
Fady Malik
executiveNo, I believe you put that nicely. I think what we're doing to get ready is pursuing every bit of the regulatory and HTA input that you brought up, and on top of that, thinking through how a protocol might ultimately be locked down. It's definitely our intention to be in a position to weigh kicking off that trial once we have a sense of how GALACTIC reads out.
Robert Blum
executiveTed, the second portion of what you asked concerned CK-601. As with every one of our programs, CK-601 serves as a backup and follow-on to the compounds that came before it, and our view is that it possesses certain attributes that could make it appropriate for advancement, possibly even in additional indications. One might picture, for example, reldesemtiv moving ahead in ALS and rare neuromuscular diseases. One might picture CK-601 moving ahead either in those very same indications or possibly even in indications outside neuromuscular. For example, as we consider extending our skeletal muscle franchise into non-neuromuscular indications. Certain indications might even overlap between our cardiac and skeletal muscle programs. Consistent with our strategy of being a pioneer and leader in muscle biology, this fits within that strategy, and CK-601 stands as one more vector, so to speak, for value creation.
Edward Tenthoff
analystUnderstood, that reasoning makes sense — I hadn’t thought about it that way. Just one quick thing for Ching. Ching, it looked a bit high, and I think the press release also referenced stock-based compensation, which obviously is connected in part to how strongly the share price has performed. Is any of that tied to pre-commercial opportunities? Based on roughly where Q1 stands, if you annualize it, it lands a little above the upper bound of your OpEx guidance. I’m just trying to get a sense of what Cytokinetics’ sales expenses might look like for the rest of the year. Thanks.
Ching Jaw
executiveThanks, Ted. Good question. You’re right that the first-quarter burn rate was $30 million. When you put that on an annual basis, it comes out above the outlook we provided. One reason for this is that our accounts payable balance at the close of 2019 was a bit above what we'd typically see. We expected the larger-than-usual cash burn in the first quarter, and it was factored into the guidance we issued.
Edward Tenthoff
analystFantastic, I really appreciate it. Everyone, take care of yourselves.
Robert Blum
executiveThanks a lot.
Ching Jaw
executiveThank you, Ted.
Robert Blum
executiveHello, Jeff.
Jeff Hung
analystHey. Thanks for taking the questions.
Robert Blum
executiveSure.
Jeff Hung
analystRegarding GALACTIC, if you can see enough to say, could you describe how frequently events have been happening since that second interim analysis? And when we hit the number of events we're aiming for, could you remind us how long you expect to need for things like cleaning up the data and analyzing it?
Robert Blum
executiveSure. That's a good question. Fady, would you like to handle that?
Fady Malik
executiveSure, I'll handle that. I'm not really in a position to speak to specifics about how event rates have shifted; broadly speaking, at the macro level, as you're aware, patients aren't showing up at hospitals as often as they used to for a lot of conditions, cardiovascular ones included. That being said, our trial's endpoint is driven by cardiovascular death, and I don't believe that rate has been meaningfully impacted recently. It's still too soon to say. These things can lag; we're just a few months in. With that said, Amgen updated the last patient, last visit timing on clinicaltrials.gov to August 7th not long ago. That's an estimate right now, but I think it gives a sense of when we expect that event to happen. Once the final event needed to bring the trial to a close occurs, it's a large trial. There's substantial data cleanup and event adjudication work ahead. You have to collect documents from as many as 35 countries where events might have taken place. There are multiple logistical pieces involved, and planning is underway right now to support getting those events and adjudication data quickly. I believe we'd be on schedule to read that out in Q4, but I can't give you anything more precise than that. Sorry, Jeff.
Jeff Hung
analystSure, that's fine. Thank you. Any news, I suppose, regarding the commercial prep work for omecamtiv before the GALACTIC readout comes out?
Robert Blum
executiveYes. Alongside Amgen, we're extremely occupied with those efforts, and a portion of the higher spending that Ching and Robert pointed to is tied to greater G&A costs connected with getting ready on the commercial side. Together with Amgen, we're laying out plans and holding meetings on launch readiness tied to a possible commercial launch during the second half of 2021, which puts us right in the middle of that launch window. That being the case, we need to keep sharpening how we position ourselves. We need to finalize a great deal of our strategies, whether that involves contracting and payers or the possibility of co-promotion. Given all this, our plan is to work out a deal with Amgen during this year granting us the rights and duties tied to that co-promotion, plus clarity for both sides regarding which role would belong to us, which would belong to them, how those would line up, and where those individuals would collaborate. Every bit of that has to happen within this year so we can be positioned as strongly as possible to be ready for our commercialization program in the following year. Both organizations have ramped up resources — through hiring and other means — so that this can be achieved, and I'm quite happy that we're seeing strong visibility and strong commitment at both organizations.
Jeff Hung
analystGreat. Thanks.
Robert Blum
executiveThank you.
Robert Blum
executiveAlright. I should apologize for dropping off the call and missing some of those questions, but I'm pleased our team members could respond to them; anyone on this call whose question went unanswered, please reach out to us afterward. These really are remarkable times; we understand that, and I hope it's clear that Cytokinetics is looking ahead and fulfilling the important strategic goals for 2020, and that from a financial and operational standpoint we're advancing from a strong place and in a strong manner. At the same time, we acknowledge we're shifting into a new normal, and alongside that new normal, we aim to be as nimble and adaptive as possible so we can fulfill the promise of our science. With that, we anticipate updating you on our progress throughout the rest of the year. We appreciate everyone who joined the teleconference today for your ongoing support and interest in Cytokinetics. Operator, we're ready to end the call now. Thank you.
Operator
operatorThank you for attending today's presentation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.